Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 3 · 37.5%Moderate 2 · 25%High 0 · 0%

Methotrexate vs alternative disease‐modifying antirheumatic drugs

Serious adverse events(4 months) · children and young people with JIA

Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.69]
1 study · 94 participants
Low

Methotrexate vs placebo

Serious adverse events(up to 6 months) · children and young people with JIA

Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 0.63 [0.04, 8.97]
3 studies · 328 participants
Low

Methotrexate vs placebo

SAEs · psoriatic arthritis

Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
RR 0.26 [0.03, 2.26]
3 studies · 293 participants
Low

Methotrexate vs other DMARDs

Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 61 participants
Very low

Methotrexate vs other DMARDs

Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Very low

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).

1 finding from 1 review

Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
RR 1 [0.69, 1.5]
4 studies · 1280 participants
Moderate

Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone

Serious adverse events(12 months) · children and young people with JIA

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Serious Adverse Events · patients with rheumatoid arthritis

The intervention showed no clear difference in serious Adverse Events (moderate certainty).

1 finding from 1 review

Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
RR 1.4 [0.36, 5.7]
2 studies · 330 participants
Moderate